A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

Por Pacey, Simon, Wilson, Richard H., Walton, Mike, Eatock, Martin M., Hardcastle, Anthea, Zetterlund, Anna, Arkenau, Hendrik-Tobias, Moreno-Farre, Javier, Banerji, Udai, Roels, Belle, Peachey, Heidi, Aherne, Wynne, de Bono, Johan S., Raynaud, Florence, Workman, Paul, Judson, Ian
Publicado em 2011